ABSTRACT Sustained therapy with nitroglycerin (NTG) has been reported to provoke the development of early tolerance. Because continuous intravenous NTG infusion is commonly used in patients with coronary artery disease and heart failure, we evaluated the incidence of early tolerance developed within the first 24 hr of therapy in 31 responders to NTG. 
ABSTRACT Sustained therapy with nitroglycerin (NTG) has been reported to provoke the development of early tolerance. Because continuous intravenous NTG infusion is commonly used in patients with coronary artery disease and heart failure, we evaluated the incidence of early tolerance developed within the first 24 hr of therapy in 31 responders to NTG. After documentation of response to NTG, defined as a 10 mm Hg or greater or a 30% or greater reduction in mean pulmonary arterial wedge pressure (PAWP), 16 patients were blindly, randomly assigned to receive placebo and 15 patients were continued on same-dose NTG. Both groups showed an identical fall in PAWP at peak NTG titration (1 1 + 4 mm Hg). Discontinuation of NTG in the placebo group resulted in a rapid increase in PAWP to levels not significantly different from baseline (19 5 mm Hg at 2 hr vs 23 6 mm Hg at baseline; p = NS). In the NTG group, PAWP fell from 27 9 to 14 ± 7 mm Hg, was 16 ± 9 mm Hg at 2 hr (p < .05 vs baseline), and continued to be significantly lower than baseline for 8 hr; however, due to attenuation of effect, PAWP values at 12, 20 , and 24 hr were not significantly different from placebo or baseline values. Analysis of individual data showed there were eight patients (group A) who had a persistent effect and seven patients (group B) who developed tolerance, which was defined as an increase in PAWP to values within 10% of baseline or a greater than 34% increase (2 x coefficient of variation ofPAWP in the placebo group 2 to 24 hr after discontinuation of NTG) from values measured at the end of NTG titration. These two groups differed only in their baseline systemic vascular resistance (2195 + 765 vs 1517 + 355 dyne-sec-cm-5; p < .05). No difference was found in any other baseline hemodynamic or hormonal variables or in the magnitude of hemodynamic change during peak NTG titration and hormonal changes during the study. This study therefore provides further evidence for the development of early tolerance to the hemodynamic effects of continuous NTG administration. Tolerance is developed in approximately half of patients with coronary artery disease and heart failure. Patients with the following conditions were not allowed in the study: (1) angiographic evidence of left main CAD, (2) unstable angina, (3) hypertension, (4) primary valvular disease, (5) pulmonary edema, (6) thyrotoxicosis, or (7) recent acute myocardial infarction within 30 days before the initiation study.
Forty patients were enrolled into the study, including 29 men and 11 women, aged 45 to 77 years (mean + SD 59 + 8). The diagnosis of CAD was based on angiographic findings in 38 patients and on history of myocardial infarction documented by typical changes in the electrocardiogram and serum myocardial enzymes in two patients. Left ventricular ejection fraction was measured in 36 patients and ranged from 0. 10 to 0.68 (mean 0.30 ± 0. 14). All patients had symptoms of heart failure for a period of at least 1 month.
Hemodynamic measurements and computations. Right heart catheterization was performed with a balloon-tipped, triple-lumen, Swan-Ganz catheter, which allowed the measurements or right atrial and pulmonary arterial pressure as well as PAWP. The reference point for the procedure was at the midchest level with the patient in a supine position. All pressures were recorded on Electronics for Medicine AR 6 or VR 12 recorders, and mean pressures were measured with the use of electronic integration. Heart rate was determined by electrocardiographic recording and systemic blood pressure was measured by the standard cuff method. Cardiac output was determined by the thermodilution technique, as previously described. 10 Measurements were preformed in triplicate with ice-cold 5% dextrose in water as the indicator. Mean arterial blood pressure, cardiac index, stroke volume index, left ventricular stroke work index, systemic vascular resistance, and pulmonary vascular resistance were calculated by standard formulas. 1' The determination of plasma levels of epinephrine and norepinephrine was performed with an isotope radioenzymatic technique. 12 Plasma renin activity was measured by radioimmunoassay. 1 3 Plasma levels of nitroglycerin were assayed by a method similar to that described by Settlage et al. 14 using gas chromatography/negative ion mass spectrometry with on-column injection (Cal Lab East, Richmond, VA). The coefficient of variation was 4.08% for intra-assay and 13. 1 % for interassay precision.
Study protocol. All patients were studied in a stable clinical 578 condition. Usual doses of digitalis, diuretic agents, and antiarrhythmic drugs were continued throughout the study. All long-acting vasodilators were withheld for at least 24 hr before the initiation of the study. Because of reported spontaneous hemodynamic changes after insertion of the pulmonary arterial catheter, ' Measurements of plasma hormones. Blood samples for catecholamines and renin were drawn at baseline, at the end of NTG titration, at 24 hr of constant drug infusion, and 30 min after discontinuation of the drugs.
Measurements of plasma NTG level. Plasma NTG levels were measured at the end of NTG titration and at 24 hr of constant NTG infusion in a sample of five consecutive patients who were found at the end of the study to have received NTG.
Statistical analysis. One-way repeated measures analysis of variance (ANOVA) and the Newman-Keuls test used to evaluate the temporal hemodynamic effects of the study drugs in each group, and single comparisons were performed with Student's t test. Coefficient of variation was calculated as standard deviation of the mean/mean x 100. Analyses were performed with the use of the CLINFO system and the SAS statistical package on the IBM 370 system at the University of Southern California. All values are expressed as mean + SD. A p value of less than .05 was considered statistically significant.
Results
Nineteen of 40 patients were initially assigned to be treated with NTG, and the other 21 patients were assigned to receive placebo. No significant differences were found between these two groups in age, duration of symptoms of heart failure, left ventricular ejection fraction, and measured or calculated baseline hemodynamic values (table 1) .
Five of the patients were excluded from the study because of failure to achieve the desired PAWP response to open-label NTG titrated to its maximum dose of 560 gg/min. Three of these patients were assigned to receive NTG therapy and two were assigned to receive placebo. One patient who was assigned to receive placebo was excluded because the baseline figure 1 . Coefficient of variation of PAWP was measured in each patient between 2 and 24 hr after discontinuation of NTG; the mean value for the entire group was 17%.
NTG group. As in the placebo group, NTG titration resulted in a significant fall in mean pulmonary arterial pressure and PAWP without a statistically significant change in other measured or calculated hemodynamic values. Mean pulmonary arterial pressure fell from 39 ± 10 to 24 ± 8 mm Hg (p < .05) and remained significantly lower than baseline values for 12 hr. Values measured at 20 and 24 hr of therapy were not statistically different from baseline. Mean PAWP demonstrated a similar change and fell from 27 ± 9 to 14 ± 7 mm Hg at peak NTG titration. Although values remained lower than baseline for the entire study duration, a gradual increase in PAWP was found and the decrease in PAWP at 12 hr was no longer statistically significant (figure 1).
Comparison of changes in PAWP between the two treatment groups. Figure 2 demonstrates the change in PAWP from control in the 16 patients receiving placebo and in the 15 patients receiving NTG. Both groups showed an identical fall in PAWP at peak NTG titration (1 1 ± 4 mm Hg). However, discontinuation of NTG Figure 3 graphically depicts changes in PAWP from baseline values in the two NTG groups (A and B) and in 16 patients treated with placebo. Changes in PAWP from baseline showed significant difference between group A and the control group starting a 2 hr and persisting for the entire study duration. In contrast, the changes from baseline in group B were different from changes in the control group only during the early part of the study, and values at 12 hr (-2 ± The change in plasma hormonal levels is demonstrated in figure 5 for the two groups. A tendency for elevation in plasma renin activity was seen at peak NTG titration and at 24 hr in group A. The changes, however, were not significant when compared with baseline values. Similarly, no significant changes were seen in the levels of both epinephrine and norepinephrine during the infusion of NTG or after its discontinuation in the two groups of patients treated with this drug.
Plasma NTG levels. The measurements of plasma NTG levels were preformed in a sample of five consecutive patients treated with NTG during peak drug titration and at 24 hr of NTG infusion (figure 6). Mean NTG plasma level was 21,200 + 6768 pg/ml at peak NTG titration and 20,299 + 7986 pg/ml at 24 hr of NTG titration. These two values were not significantly different. In spite of persistence of NTG in plasma, in these patients PAWP was significantly higher (p < .05) at 24 hr (27 ± 9 mm Hg) than at peak NTG titration (22 + 9 mm Hg).
Discussion
These results clearly demonstrate the development of tolerance to the hemodynamic effects of intravenous infusion of NTG occurring within the first 12 hr of therapy in approximately half of our patients. The findings of persistent NTG blood levels at the end of the study showed that the attenuation of the effects of NTG was not caused by a reduction in drug concentration in the blood. These findings bear important clinical implications and reemphasize the potential therapeutic limitations of NTG when given in a continuous, uninterrupted fashion in patients with CAD and heart failure. The relationship between continuity of exposure to organic nitrates and the development of tolerance to their vasodilatory effect was first demonstrated in animal experiments.16' 17 Recent investigations of the effects of continuous NTG administration via transdermal systems have also demonstrated a development of early tolerance to the hemodynamic and anti-ischemic effects in patients with angina pectoris and heart failure.8 1821
Individual analysis of our data shows that not all patients develop tolerance to the effects of NTG; approximately half of the patients maintained their initial response to the drug. This conclusion may be limited by the fact that the duration of the study was restricted to 24 hr and tolerance to NTG may occur later in some patients. Although this possibility cannot be excluded by our results, the findings in this study and others suggest that tolerance to NTG when administered continuously is an early phenomenon that occurs within several hours of therapy. 21 22 An ability to predict the development of tolerance in patients treated with intravenous NTG would be of obvious clinical importance. 
